HS-131

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

HS-131 

HS-131 是一种近红外 Hsp90 的染料抑制剂，能够检测原癌基因驱动的乳腺癌，并能识别不同的人类乳腺癌分子亚型。

HS-131

HS-131 Chemical Structure

CAS No. : 2084850-40-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

HS-131, a near infrared dye tethered Hsp90 inhibitor, is able to detect oncogene-driven breast cancers, including multiple different molecular subtypes of human breast cancers[1].

体外研究
(In Vitro)

Immunofluorescence[1]

Cell Line: Tumor cells.
Concentration: 10 µM.
Incubation Time: 30 min.
Result: Tissues/organs, including eyes, brain, heart, lung, liver, spleen, kidney, gut, urinary bladder and skin, were imaged ex vivo by the IVIS imager machine, an imaging modality that detects IR at 640 nm.

体内研究
(In Vivo)

HS131 (10 nmol/mouse) could label breast cancers with different molecular subtypes, including MCF-7 and T-47D for luminal type, BT474M1 and KPL-4 for HER2+ subtype, MDA-MB-231 and MDA-MB-468 for triple negative subtype were chosen after considering the tumorigenic capacities of breast cancer cell lines in SCID mice[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SCID-beige mice bearing human breast cancer xenografts of different molecular subtypes[1].
Dosage: 10 nmol/mouse.
Administration: Injected intravenously.
Result: All breast cancer xenografts with different molecular subtypes showed stronger nIR signals in tumor by intravenous administration of HS131 compared to HS152, and the retention of the nIR signals was detectable even at the 24 h time point in HS131 injected mice.

分子量

1318.68

Formula

C71H95N7O13S2
CAS 号

2084850-40-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Takuya Osada, et al. In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. Clin Cancer Res. 2017 Dec 15;23(24):7531-7542.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务